Magnetoliposomes based on magnetic/plasmonic nanoparticles loaded with tricyclic lactones for combined cancer therapy

dc.contributor.authorRio, Irina Soraia Rainhopor
dc.contributor.authorRodrigues, Ana Rita Oliveirapor
dc.contributor.authorRodrigues, Juliana M.por
dc.contributor.authorQueiroz, Maria João R. P.por
dc.contributor.authorCalhelha, R. C.por
dc.contributor.authorFerreira, Isabel C. F. R.por
dc.contributor.authorAlmeida, B. G.por
dc.contributor.authorPires, Anapor
dc.contributor.authorPereira, André M.por
dc.contributor.authorAraújo, João P.por
dc.contributor.authorCastanheira, Elisabete M. S.por
dc.contributor.authorCoutinho, Paulo J. G.por
dc.date.accessioned2022-01-05T14:55:54Z
dc.date.available2022-01-05T14:55:54Z
dc.date.issued2021-11-10
dc.description.abstractLiposome-like nanoarchitectures containing manganese ferrite nanoparticles covered or decorated with gold were developed for application in dual cancer therapy, combining chemotherapy and photothermia. The magnetic/plasmonic nanoparticles were characterized using XRD, UV/Visible absorption, HR-TEM, and SQUID, exhibiting superparamagnetic behavior at room temperature. The average size of the gold-decorated nanoparticles was 26.7 nm for MnFe2O4 with 5-7 nm gold nanospheres. The average size of the core/shell nanoparticles was 28.8 nm for the magnetic core and around 4 nm for the gold shell. Two new potential antitumor fluorescent drugs, tricyclic lactones derivatives of thienopyridine, were loaded in these nanosystems with very high encapsulation efficiencies (higher than 98%). Assays in human tumor cell lines demonstrate that the nanocarriers do not release the antitumor compounds in the absence of irradiation. Moreover, the nanosystems do not cause any effect on the growth of primary (non-tumor) cells (with or without irradiation). The drug-loaded systems containing the core/shell magnetic/plasmonic nanoparticles efficiently inhibit the growth of tumor cells when irradiated with red light, making them suitable for a triggered release promoted by irradiation.por
dc.description.sponsorshipThis research was funded by the Portuguese Foundation for Science and Technology (FCT) in the framework of the Strategic Funding of CF-UM-UP (UIDB/04650/2020) and through the research project PTDC/QUI-QFI/28020/2017 (POCI-01-0145-FEDER-028020), financed by the European Fund of Regional Development (FEDER), COMPETE2020, and Portugal2020. I.S.R.R. acknowledges FCT for a research grant under CF-UM-UP Strategic Funding (UID/FIS/04650/2019) and a PhD grant (2020.04431.BD). J.M.R. acknowledges FCT, ESF (European Social Fund—North Portugal Regional Operational Program) and HCOP (Human Capital Operational Program) for a PhD grant (SFRH/BD/115844/2016). The APC was also financed by FCT.por
dc.distributioninternationalpor
dc.identifier.articlenumber1905por
dc.identifier.citationRio, I.S.R.; Rodrigues, A.R.O.; Rodrigues, J.M.; Queiroz, M.-J.R.P.; Calhelha, R.C.; Ferreira, I.C.F.R.; Almeida, B.G.; Pires, A.; Pereira, A.M.; Araújo, J.P.; Castanheira, E.M.S.; Coutinho, P.J.G. Magnetoliposomes Based on Magnetic/Plasmonic Nanoparticles Loaded with Tricyclic Lactones for Combined Cancer Therapy. Pharmaceutics 2021, 13, 1905. https://doi.org/10.3390/pharmaceutics13111905por
dc.identifier.doi10.3390/pharmaceutics13111905por
dc.identifier.eissn1999-4923
dc.identifier.urihttps://hdl.handle.net/1822/75227
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)por
dc.relationPTDC/QUI-QFI/28020/2017por
dc.relationUIDB/04650/2020por
dc.relationUID/FIS/04650/2019por
dc.relationSFRH/BD/115844/2016por
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/13/11/1905por
dc.rightsopenAccesspor
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/por
dc.subjectmanganese ferrite/gold nanoparticlespor
dc.subjectmagnetoliposomespor
dc.subjectnew antitumor drugspor
dc.subjectthienopyridine derivativespor
dc.subjectcombined cancer therapypor
dc.subject<p>manganese ferrite/gold nanoparticles</p>por
dc.subjectgold nanoparticlespor
dc.subject.fosEngenharia e Tecnologia::Nanotecnologiapor
dc.subject.odsSaúde de qualidadepor
dc.subject.odsProdução e consumo sustentáveispor
dc.subject.odsProteger a vida terrestrepor
dc.subject.wosScience & Technologypor
dc.titleMagnetoliposomes based on magnetic/plasmonic nanoparticles loaded with tricyclic lactones for combined cancer therapypor
dc.typearticlepor
dspace.entity.typePublicationen
oaire.citationIssue11por
oaire.citationVolume13por
oaire.versionVoRpor
sdum.journalPharmaceuticspor

Ficheiros

Pacote original

A mostrar 1 - 2 de 2
A carregar...
Nome:
pharmaceutics-13-01905.pdf
Tamanho:
4.4 MB
Formato:
Adobe Portable Document Format
Descrição:
Main document
A carregar...
Nome:
Supplementary_Pharmaceutics_Final.pdf
Tamanho:
904.39 KB
Formato:
Adobe Portable Document Format
Descrição:
Supplementary Information